Use access key #2 to skip to page content.

Teva Pharma (TEVA)



December 01, 2016 – Comments (0) | RELATED TICKERS: TEVA

The Street is wrecked over the Actavis integration and Copaxone competition.  Teva Pharma (TEVA) is a gorilla and the 3-5 year outlook is pretty good.  The Value Line low total return forecast is approximately 15% and TEVA landed at the top of of this week's Fave Five:

0 Comments – Post Your Own

Featured Broker Partners